


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)
Stock code: 2120

ANNOUNCEMENT

SHARE REPURCHASE

This announcement is made by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

References are made to the circular dated September 26, 2024 (the “**Circular**”) and the announcement dated October 14, 2024 (the “**Announcement**”) of the Company in relation to the proposed grant of general mandate to the Board to further partially repurchase H Shares. Unless the context otherwise requires, terms used in this announcement shall have the same meanings as those defined in the Circular and the Announcement.

On October 14, 2024, the Shareholders considered and approved the proposed grant of general mandate to the Board to further partially repurchase H Shares, pursuant to which the Board and the persons authorized by the Board may, during the valid period, repurchase not more than 10% of the total issued and fully paid-up H Shares of the Company (excluding H Shares that have been repurchased but not cancelled; and excluding treasury shares, if any) on the date on which the proposed grant of general mandate to the Board to further partially repurchase H Shares was approved by the EGM and the Class Meetings (i.e. a total of 1,991,000 Shares) (the “**New Repurchase Mandate**”). The New Repurchase Mandate will expire on the following dates or when the following conditions are triggered (whichever the earliest): (i) if the amount of funds used in repurchase has reached the maximum amount during the term of repurchase, the implementation of the repurchase proposal will be completed immediately, that means, the term of repurchase expires in advance with effect from that day; (ii) the conclusion of the next annual general meeting of the Company; or (iii) the date when the general mandate to repurchase H Shares has been withdrawn or amended by a special resolution approved by shareholders’ general meeting and shareholders’ class meeting of the Company.

On March 28, 2025, the Board decided to authorize Mr. Wang Jian, an executive director, to implement the New Repurchase Mandate by repurchasing not more than 1,991,000 Shares with the Company’s own funds on the Hong Kong Stock Exchange with effect from March 28, 2025 (“**Share Repurchases**”). The Company believes that the Share Repurchases reflect the Company’s long-term confidence in its business development, increase the net asset value per Share and/or earnings per Share of the Company, and are in the best interests of the Company and the Shareholders.

The Company will conduct Share Repurchases in compliance with the New Repurchase Mandate, the Listing Rules, the Takeovers Code, the Articles and other applicable laws of Hong Kong.

Shares repurchased by the Company will be cancelled by Computershare Hong Kong Investor Services Limited, the Company's Hong Kong share registrar, as soon as reasonably practicable after the delivery of such repurchases.

Shareholders and potential investors should be aware that the exercise of the New Repurchase Mandate by the Company is subject to market conditions and will be at the absolute discretion of the Board. There is no assurance as to the timing, quantity or price of any Share Repurchases, or whether the Company will make any Share Repurchases. Therefore, Shareholders of the Company and prospective investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
March 28, 2025

As at the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Mr. WANG Jian; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Ms. ZHONG Wentang, Ms. JIN Ling and Mr. CHAN Sai Keung Hugo.